1. Scrip
  2. >>New Products

US Approval Of Vabomere Could Help Alleviate TMC's Financial Troubles

 
• By Michael Cipriano

The antibiotic Vabomere demonstrated statistical superiority over Zosyn, and could be a more attractive option than existing treatments for complicated urinary tract infections.

Illustration of bacteria on colorful background, model of bacteria, microbes, microorganisms,

The Medicines Co. hopes the favorable efficacy and safety labeling that the US FDA approved for Vabomere will help the novel antibiotic break into the hospital market for complicated urinary tract infections (cUTI) – and help alleviate the company's financial woes.

Intravenous Vabomere combines a novel beta-lactamase inhibitor (BLI), vaborbactam, with the penem antibiotic meropenem (Pfizer Inc.'s Merrem and generics). FDA approved Vabomere on Aug. 29 for the treatment of adults with cUTI, including the kidney infection pyelonephritis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.